TKM-PLK1 / Arbutus - LARVOL DELTA

An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. (PubMed, Oncologist) - "TKM-080301 was generally well tolerated. In this early-phase study, antitumor effect for TKM 080301 was limited. Further evaluation as a single agent in large randomized trials is not warranted."

Clinical • Journal • P2 data • PK/PD data • Gastrointestinal Cancer • Hematological Disorders • Hepatocellular Cancer • Oncology • Thrombocytopenia

Tekmira: BIO CEO and Investor Conference (Tekmira Pharmaceuticals Corporation) - "Administered to 23 patients at doses ranging from 0.15 mg/kg to 0.90 mg/kg with a total of 128 doses"; "One patient with a partial response at 0.60 mg/kg having received 23 doses over 8 months"; "One patient attained stable disease at 0.6 mg/kg having received 18 doses over 6 months"

P1 data • Oncology

The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market. (PubMed) - Pharm Res - "...The siRNAs in focus are PF-04523655, TKM-080301, Atu027, SYL040012, SYL1001, siG12D-LODER (phase 2), QPI-1002, QPI-1007, and patisiran (phase 3)...Miravirsen is an AntimiR-122 for hepatitis C virus infection. The flexibility of RNAi technology is easily understood taking into account: (i) the different drug targets (i.e. p53, caspase 2, PKN3, β2-adrenergic receptor, mutated KRAS, microRNAs); (ii) therapeutic conditions, including ophthalmic diseases, kidney injury, amyloidosis, pancreatic cancer, viral hepatitis; and (iii) routes of administration (ocular, intravenous, subcutaneous, intratumoral). Although some issues are still matters of concern (delivery, toxicity, cost, and biological barriers), RNAi definitively opens a wide avenue for drug development."

Journal • Review • Biosimilar • Gastrointestinal Cancer • Hepatitis C Virus • Immunology • Oncology • Ophthalmology • Pancreatic Cancer • Renal Disease